



To Our Valued Vendors:

On September 15, 2019, Purdue reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with 24 state attorneys general, analogous officials from 5 U.S. territories, the Plaintiffs' Executive Committee in the multidistrict litigation (MDL), and co-lead counsel in the MDL. The settlement structure is estimated to provide more than \$10 billion of value to address the opioid crisis.

To implement this settlement and secure a global resolution of all pending litigation, Purdue and all of its subsidiaries have voluntarily filed for reorganization under Chapter 11 of the U.S. Bankruptcy Code. Upon emergence from the chapter 11 process, Purdue will be converted to a trust or other entity for the benefit of claimants and the U.S. public. In addition to 100% of Purdue, the Sackler families will contribute a minimum of \$3 billion, with the potential for substantial further monetary contributions from the sales of their ex-U.S. pharmaceutical businesses. The Company also intends to contribute tens of millions of doses of opioid overdose reversal medications and opioid use disorder treatment medications, including nalmeferne, naloxone and buprenorphine-naloxone combination products to help combat the opioid addiction crisis.

Filing for chapter 11 is the only way to implement a settlement that can deliver billions of dollars of value and critical help in combatting the opioid addiction crisis for the benefit of the American people; resolve the litigation that we are facing fully and efficiently; preserve the value of our company; and enable fair and efficient centralized resolution of all claims we face. It is important to note that the decision to file for chapter 11 was unrelated to the financial health of our company. Purdue currently has more than \$1 billion in cash on hand, and ample liquidity to continue to manage our operations. We remain focused on serving our customers and meeting our obligations to all stakeholders during this process.

Purdue's restructuring as a public benefit entity will ensure that our FDA-approved medicines and other products will continue to be available to patients who need them, and that Purdue can continue to develop and distribute opioid overdose reversal medications and opioid use disorder treatment medications, consumer health and wellness products, and important new therapies to treat cancer, pain, ADHD and disorders of the central nervous system.

We plan to operate "business as usual" during this process and we expect minimal impact on our day-to-day activities. Vendors with specific questions regarding product deliveries or payments for goods and services can contact vendorinquiries@pharma.com for more information.

We will keep you informed should any changes occur that would impact your relationship with us. We appreciate your business and look forward to continuing our work together.

Any questions can be directed to our restructuring information line at +1 (844) 217-0912 (or, if you are calling from outside the U.S. or Canada, +1 (347-859-8093).

Case documents may also be found at <https://restructuring.primeclerk.com/purduepharma>.